Vipond Caroline, Suker Janet, Jones Christopher, Tang Christoph, Feavers Ian M, Wheeler Jun X
Department of Bacteriology, National Institute for Biological Standards and Control, South Mimms, Hertfordshire, UK.
Proteomics. 2006 Jun;6(11):3400-13. doi: 10.1002/pmic.200500821.
In the absence of a suitable carbohydrate-based vaccine, outer membrane vesicle (OMV) vaccines have been used to disrupt outbreaks of serogroup B meningococcal disease for more than 20 years. Proteomic technology provides physical methods with the potential to assess the composition and consistency of these complex vaccines. 2-DE, combined with MS, were used to generate a proteome map of an OMV vaccine, developed to disrupt a long-running outbreak of group B disease in New Zealand. Seventy four spots from the protein map were identified including the outer membrane protein (OMP) antigens: PorA, PorB, RmpM and OpcA. Protein identification indicates that, in addition to OMPs, OMV vaccines contain periplasmic, membrane-associated and cytoplasmic proteins. 2-D-DIGE technology highlighted differences between preclinical development batches of vaccines from two different manufacturers.
在缺乏合适的基于碳水化合物的疫苗的情况下，外膜囊泡（OMV）疫苗已被用于控制B群脑膜炎球菌病的暴发20多年。蛋白质组学技术提供了评估这些复杂疫苗组成和一致性的物理方法。二维电泳（2-DE）结合质谱（MS）用于生成一种OMV疫苗的蛋白质组图谱，该疫苗旨在控制新西兰一场持续已久的B群疾病暴发。从蛋白质图谱中鉴定出74个斑点，包括外膜蛋白（OMP）抗原：PorA、PorB、RmpM和OpcA。蛋白质鉴定表明，除了OMPs外，OMV疫苗还包含周质、膜相关和细胞质蛋白。二维差异凝胶电泳（2-D-DIGE）技术突出了来自两家不同制造商的临床前开发批次疫苗之间的差异。
